Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.51 |
| ▸ | RARA | P10276 | 7/20 | 0.51 |
| ▸ | RARG | P13631 | 7/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177290 | 0.89 | RARB (0.62) | RARBRARARARGALOX15ALDH1A1 | |
| SCHEMBL4431042 | 0.74 | RARB (0.55) | RARBRARARARGALDH1A1RXRA | |
| SCHEMBL7667567 | 0.72 | RXRA (0.46) | RARBRARARARGALOX15ALDH1A1 | |
| SCHEMBL6176369 | 0.72 | RARB (0.58) | RARBRARARARGALDH1A1KDM4E | |
| SCHEMBL7674825 | 0.70 | RARB (0.54) | RARBRARARARGRXRARXRB | |
| SCHEMBL7674828 | 0.70 | RARB (0.54) | RARBRARARARGRXRARXRB | |
| SCHEMBL22411137 | 0.70 | RARB (0.55) | RARBRARARARGKDM4E | |
| SCHEMBL7671013 | 0.69 | RARB (0.50) | RARBRARARARGRXRA | |
| SCHEMBL7669825 | 0.69 | RARB (0.50) | RARBRARARARGRXRA | |
| SCHEMBL6175867 | 0.69 | RARB (0.50) | RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559709-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | Eisai Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-0838453-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-6884808-B2 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6630463-B2 | Such as 4-(4-(2-(2-(5,6,7,8-tetrahydro-5,5,8,8 -tetramethylquinoxalyl))pyrrolyl))benzoic acid; for treatment of acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2003-07-31 | — | — | US | disclosed |
| US-6541474-B2 | Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia | EISAI CO. LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | EISAI CO. LTD. | 2002-03-14 | — | — | US | disclosed |
| US-6329402-B1 | FOR THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA | EISAI CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-5977108-A | LEUKEMIA | EISAI CO., LTD (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0838453-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103234-A1 | Heterocycl-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | RARB 2/4885RARA 1/4885RARG 3/4885 |
| US-20030144276-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | RARB 2/4885RARA 1/4885RARG 3/4885 |
| US-20020032202-A1 | Heterocycle-containing carboxylic acid derivative and drug containing the same | RARA, RARB, RARG | RARB 2/4885RARA 1/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.